News

OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of BCX4161, 300 mg and 500 mg, administered three-times daily

The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in

The BLA was based on results from the LEOPOLD clinical trials, which evaluated BAY 81-8973 in adults and children using two- and three-times-per-week prophylaxis dosing regimens. BAY 81-8973,

The trial met its primary endpoint showing that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo. HZ/su is

Terms of the transaction were not disclosed. The deal is said to strengthen KCR’s presence in Ukraine, making the country an important location for the firm in the

The drug is approved for patients who are in complete response or partial response to platinum-based chemotherapy. Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumor

The company uses its Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body’s

The two products have been approved by Health Canada and are indicated for the treatment of hypertension or high blood pressure. Hypertension occurs when the blood pressure in

The amendment to the Supply Agreement between Alexza and Autoliv, signed on December 11, 2014, updates certain terms of prior agreements between the companies. The Amendment states that